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Brittany (France). Main data about clinical presentation and management were
compared according to the gender.
Results: Among 5000 patients included in the ORBI registry, 1174 patients
(23.5%) were women (mean age: 68.814 vs 60.812 for men, p0.0001), with
significant differences in their cardiovascular risk factors, especially hypertension
(54 vs 36%, p0.0001), dylipidemia (44 vs 52%, p0.0001) and current smoking
(25 vs 51%, p0.0001). As presented in table 1, there are some significant
differences in the management of women: delays of reperfusion are longer,
partially due to longer delays between symptom onset and call for medical
assistance. Thrombolytic agents are less used in women, and coronary angiogra-
phy is less performed. Moreover, morbi-mortality is higher in women: intra
hospital women mortality is 9.0%, vs 4.4% for men (p0.0001). Last, there is a
significant underused in all of the recommend treatments at discharged.
Men n  3826 Women n  1174 p
Chest pain as the 1st
symptom
3445 (95%) 1039 (93%) 0.03
Initial Management Delay* (min.) between:
- symptom onset and call
for medical assistance
44 162 60 187 <0.0001
- delay between admission
and reperfusion**
40 42 45 51 0.011
Fibrinolysis 618 (16%) 143 (12%) 0.001
Glycoprotein IIb/IIIa
receptor inhibitors
2269 (59%) 628 (53%) <0.0001
Coronary angiography 3773 (98%) 1122 (95%) <0.0001
Radial access 1348 (51%) 303 (38%) <0.0001
Primary angioplasty 2754 (72%) 829 (70%) 0.36
Thrombo aspiration 1612 (47%) 425 (43%) 0.075
Intra hospital
morbi-mortality
High degree atrio-
ventricular block
112 (2%) 68 (5%) <0.0001
Atrial fibrillation 138 (3%) 82 (7%) <0.0001
FEVG 50.5 10 49.4 11 0.004
Deaths 167 (4%) 106 (9%) <0.0001
Total length of stay 6.7 4 7.6 4 <0.0001
Prescription at
discharge
Aspirine 3584 (98%) 1022 (95%) <0.0001
Clopidogrel/Prasugrel 3506 (95%) 993 (93%) <0.0001
Beta blockers 3349 (91%) 940 (88%) 0.001
Angiotensin-converting
enzyme inhibitor
2481 (67%) 662 (62%) <0.0001
Statine 3475 (95%) 955 (89%) <0.0001
Cardiovascularrehabilitation 1577 (47%) 267 (27%) <0.0001
*Delays are presented as median standard deviation.
**For patients treated by a primary angioplasty.
Conclusions: Despite numerous awareness campaigns about management of STEMI in
women, it still includes significant differences, resulting a higher morbidity and mortality.
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Background: Everolimus-eluting stents (EES) improve safety compared with early-
generation sirolimus-eluting (SES) and paclitaxel-eluting stents (PES). However, it is
unknown whether the benefits in terms of safety are consistent among female and male
patients.
Methods: A total of 12,339 consecutive patients were treated at 2 academic institutions
between 2002 and 2009. 11,954 patients – 3,112 women (26%) and 8,842 men (74%) –
completed last follow-up and were included in this analysis. EES were implanted among
1,100 women (35%) and 3,001 men (34%), whereas early-generation SES or PES were
used among 2,012 women (65%) and 5,841 men (66%). We performed a stratified
analysis of clinical outcomes between EES and early-generation SES or PES according to
gender. Adjustment was performed with inverse probability of treatment weighting.
Primary endpoint was ARC definite stent thrombosis (ST).
Results: During follow to 4 years (median 2.9 years), the use of EES reduced the risk of
definite ST to a similar extent in women (RR 0.41, 95%CI 0.28-0.59) and men (RR 0.40,
95%CI 0.20-0.78; p-interaction0.95) compared with early-generation SES and PES.
This was paralleled by a similar reduction in the risk of myocardial infarction with EES
over early-generation SES and PES among women (RR 0.59, 95%CI 0.46-0.77) and men
(RR 0.47, 95%CI 0.29-0.75; p-interaction0.52), as well as the composite of cardiac
death and myocardial infarction among women (RR 0.72, 95%CI 0.61-0.84) and men
(RR 0.82, 95%CI 0.65-1.04; p-interaction0.32). In addition, EES provided a compara-
ble efficacy benefit in terms of target-vessel revascularization among women (RR 0.69,
95%CI 0.59-0.80) and men (RR 0.52, 95%CI 0.39-0.70; p-interaction0.32) compared
with early-generation SES and PES.
Conclusions: Newer generation EES provide a similar safety benefit among women and
men, with a consistent reduction in the risk of definite ST and myocardial infarction
compared with early-generation SES and PES during long term follow-up.
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Background: Aging society has changed the component of the population in world wide,
especially Japanese is the most progressive. Therefore, classifying elderly patients,
particularly those 75 years and older, as a single cluster may overlook differences in
elderly patients. The aim of this study was to investigate how difference of clinical
characteristics and outcomes of elderly hospitalized with acute myocardial infarction
(AMI) vary based on age.
Methods: We analyzed 3723 consecutive patients who enrolled as AMI from 27
hospitals during 2005 to 2009 in Japan. We categorized patients into four groups based on
their age: younger than 65 years (n1418), 65 to 74 years (n1027), 75 to 84 years
(n935) and 85 years and older (n343).
Results: Older patients were more likely to be women and to have hypertension, renal
insufficiency, less likely to have dyslipidemia, diabetes, smoking. Primary percutaneous
coronary intervention (PCI) was performed at a high frequency in all groups (88.9% vs
86.3% vs 81.3% vs 73.8%: P0.0001, respectively). In-hospital mortality rate rose
gradually with age. (2.8 vs 6.4% vs 12.5% vs 19.8%:P0.0001, respectively), and the
same tendency can be seen whether they received primary PCI (2.6% vs 4.9% vs 9.6% vs
16.2%: P0.0001, respectively) or not (3.8% vs 16.3% vs 25.1% vs 30.0%: P0.0001,
respectively). In multivariable analysis, age was one of the important predictor of
in-hospital mortality.
Conclusions: Despite high prevalence of primary-PCI in elderly in Japan, aging is
strongly associated with in-hospital mortality.
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Background: Patients with liver disease who undergo percutaneous coronary interven-
tions (PCI) have been thought to be at high risk of adverse events. The data regarding
safety of PCI in patients with liver disease is sparse and there is no data on long-term
outcomes post-PCI.
Methods: Baseline demographic, procedure-related, and in-hospital and 1-year
adverse outcome data on consecutive patients undergoing PCI during 5 recruit-
ment waves of the National Heart, Lung, and Blood Institute (NHLBI) Dynamic
Registry across clinical centers which enrolled at least 1 patient with liver disease
were collected. Patients with liver disease (n79) were compared with patients
without liver disease (n5926).
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